NCT05394714 - A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Colon Cancer Stage I

Interventions

BIOLOGICAL

Magicell-NK contains NK cells suspended in 100 mL normal saline

Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled

Trial Locations (1)

RECRUITING

Chang Gung Memorial Hospital, Linkou, Taoyuan District